Product Code: 978-1-68038-596-0
Fluorescent In Situ Hybridization Probe Market Growth & Trends:
The global fluorescent in situ hybridization probe market size is expected to reach USD 1,485.88 million by 2030, registering a CAGR of 7.78% from 2025 to 2030, according to a new report by Grand View Research, Inc. The increasing global population being prone to target diseases, such as cancer, leads to the rising demand for accurate and effective diagnostics. This is expected to boost the market growth. For instance, according to the American Cancer Society Cancer Statistics 2023, it was estimated that approximately 1.9 million new cancer cases will be diagnosed in the U.S. in 2023. The Australian Institute of Health and Welfare (AIHW) 2021 report indicates that there were an estimated 150,782 new cancer cases in Australia in 2021.
Furthermore, the ICMR 2021 Report suggests that the number of cancer patients in India is projected to increase from 26.7 million in 2021 to 29.8 million in 2025. The fluorescent in situ hybridization (FISH) technique serves various purposes, including the precise localization of specific DNA sequences, genetic disease diagnosis, gene mapping, and identification of new oncogenes associated with different types of cancers. The growing investment in cancer genomics is expected to drive the adoption and significance of FISH. In addition, supportive government initiatives, rising healthcare expenditure levels, and increasing awareness pertaining to the benefits associated with this technique are expected to fuel industry growth during the forecast period.
Furthermore, technological advancement in chromogenic in situ hybridization (CISH), such as higher storage time of analyzed samples for long-duration studies, is expected to fuel the demand for navigation systems in the coming years. FISH is most commonly used in the detection of genetic diseases, such as Angelman syndrome, Prader-Willi syndrome, chronic myelogenous leukemia, Down's syndrome, Velocardiofacial syndrome, 22q13 deletion syndrome, acute lymphoblastic leukemia (ALL), and cri-du-chat. According to a publication from the CDC in 2022, Down's syndrome is the most common genetic disorder, with almost one in every 700 newborns affected by the disorder.
The rising prevalence of the condition drives the need to provide efficient diagnostics for detecting these genetic diseases, which, in turn, drives the overall market growth. Furthermore, key participants are engaged in various strategies, such as product launches, partnerships & collaborations, and M&As, to expand their global footprint and maintain competitive position in the market. For instance, in March 2023, OGT (Sysmex Group) received IVDR certification for CytoCell FISH probes. The company is the first manufacturer of FISH probes to receive IVDR certification, showcasing its unwavering commitment to meeting the significantly more rigorous regulatory standards. This certification validates their products' enduring safety, dependability, and efficacy.
Fluorescent In Situ Hybridization Probe Market Report Highlights:
- FLOW-FISH held the largest share of 35.81% of the fluorescent in situ hybridization probe industry in 2024 and is reported to be the fastest segment over the forecast period.
- DNA probes represent the largest segment of the market, accounting for 55.85% of revenue share, owing to their critical role in detecting specific gene sequences, chromosomal abnormalities, and structural rearrangements.
- Cancer diagnostics is the largest segment of the market, with a revenue share of 43.85% in 2024, driven by the technique's ability to detect high precision gene rearrangements, amplifications, and deletions.
- Clinical use represents the largest segment of the market, accounting for 41.33% in 2024, driven by its widespread application in diagnosing genetic disorders, cancers, and infectious diseases.
- North America dominated the fluorescent in situ hybridization probe market and accounted for a 44.33% share in 2024, driven by the high adoption of molecular diagnostics and the strong presence of key market players.
- Asia-Pacific is rapidly emerging with a CAGR of 9.5% in the FISH probe market, driven by rising awareness of genetic diseases and increasing cancer prevalence.
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Technology
- 1.2.2. Type
- 1.2.3. Application
- 1.2.4. End Use
- 1.2.5. Regional scope
- 1.2.6. Estimates and forecasts timeline.
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR's internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
- 1.5. Information or Data Analysis
- 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Approach 1: Commodity flow approach
- 1.7.3. Volume price analysis (Model 2)
- 1.7.4. Approach 2: Volume price analysis
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Technology Outlook
- 2.2.2. Application Outlook
- 2.2.3. Type Outlook
- 2.2.4. End Use Outlook
- 2.2.5. Regional outlook
- 2.3. Competitive Insights
Chapter 3. Fluorescent In Situ Hybridization Probe Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook.
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.2. Market restraint analysis
- 3.3. Fluorescent In Situ Hybridization Probe Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
- 3.3.2. PESTEL Analysis
Chapter 4. Fluorescent In Situ Hybridization Probe Market: Technology Estimates & Trend Analysis
- 4.1. Technology Market Share, 2024 & 2030
- 4.2. Segment Dashboard
- 4.3. Global Fluorescent In Situ Hybridization Probe Market by Technology Outlook
- 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 4.4.1. Q FISH
- 4.4.1.1. Q FISH market estimates and forecasts 2018 to 2030 (USD Million)
- 4.4.2. FLOW FISH
- 4.4.2.1. FLOW FISH market estimates and forecasts 2018 to 2030 (USD Million)
- 4.4.3. Others
- 4.4.3.1. Other market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. Fluorescent in situ Hybridization Probe Market: Type Estimates & Trend Analysis
- 5.1. Type Market Share, 2024 & 2030
- 5.2. Segment Dashboard
- 5.3. Global Fluorescent In Situ Hybridization Probe Market by Type Outlook
- 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 5.4.1. DNA
- 5.4.1.1. DNA market estimates and forecasts 2018 to 2030 (USD Million)
- 5.4.2. RNA
- 5.4.2.1. RNA market estimates and forecasts 2018 to 2030 (USD Million)
- 5.4.3. mRNA
- 5.4.3.1. mRNA market estimates and forecasts 2018 to 2030 (USD Million)
- 5.4.4. miRNA
- 5.4.4.1. miRNA market estimates and forecasts 2018 to 2030 (USD Million)
- 5.4.5. Other
- 5.4.5.1. Other market estimates and forecasts 2018 to 2030 (USD Million
Chapter 6. Fluorescent In Situ Hybridization Probe Market: Application Estimates & Trend Analysis
- 6.1. Application Market Share, 2024 & 2030
- 6.2. Segment Dashboard
- 6.3. Global Fluorescent In Situ Hybridization Probe Market by Application Outlook
- 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 6.4.1. Cancer Diagnostics
- 6.4.1.1. Cancer Diagnostics market estimates and forecasts 2018 to 2030 (USD Million)
- 6.4.1.2. Lung
- 6.4.1.2.1. Lung market estimates and forecasts 2018 to 2030 (USD Million)
- 6.4.1.3. Breast
- 6.4.1.3.1. Breast market estimates and forecasts 2018 to 2030 (USD Million)
- 6.4.1.4. Bladder
- 6.4.1.4.1. Bladder market estimates and forecasts 2018 to 2030 (USD Million)
- 6.4.1.5. Hematological
- 6.4.1.5.1. Hematological market estimates and forecasts 2018 to 2030 (USD Million)
- 6.4.1.6. Gastric
- 6.4.1.6.1. Gastric market estimates and forecasts 2018 to 2030 (USD Million)
- 6.4.1.7. Prostrate
- 6.4.1.7.1. Prostrate market estimates and forecasts 2018 to 2030 (USD Million)
- 6.4.1.8. Cervical
- 6.4.1.8.1. Cervical market estimates and forecasts 2018 to 2030 (USD Million)
- 6.4.1.9. Other
- 6.4.1.9.1. Other market estimates and forecasts 2018 to 2030 (USD Million)
- 6.4.1.10. Genetic diseases
- 6.4.1.10.1. Genetic diseases market estimates and forecasts 2018 to 2030 (USD Million)
- 6.4.1.11. Other
- 6.4.1.11.1. Other market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. Fluorescent in situ Hybridization Probe Market: End Use Estimates & Trend Analysis
- 7.1. End Use Market Share, 2024 & 2030
- 7.2. Segment Dashboard
- 7.3. Global Fluorescent In Situ Hybridization Probe Market by End Use Outlook
- 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 7.4.1. Research
- 7.4.1.1. Research market estimates and forecasts 2018 to 2030 (USD Million)
- 7.4.2. Clinical use
- 7.4.2.1. Clinical use market estimates and forecasts 2018 to 2030 (USD Million)
- 7.4.3. Companion diagnostics
- 7.4.3.1. Companion diagnostics market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 8. Fluorescent In Situ Hybridization Probe Market: Regional Estimates & Trend Analysis
- 8.1. Regional Market Share Analysis, 2024 & 2030
- 8.2. Regional Market Dashboard
- 8.3. Global Regional Market Snapshot
- 8.4. Market Size, & Forecasts, Trend Analysis, 2018 to 2030:
- 8.5. North America
- 8.5.1. North America: SWOT Analysis
- 8.5.2. U.S.
- 8.5.2.1. Key country dynamics
- 8.5.2.2. Regulatory framework
- 8.5.2.3. Competitive scenario
- 8.5.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
- 8.5.3. Canada
- 8.5.3.1. Key country dynamics
- 8.5.3.2. Regulatory framework
- 8.5.3.3. Competitive scenario
- 8.5.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
- 8.5.4. Mexico
- 8.5.4.1. Key country dynamics
- 8.5.4.2. Regulatory framework
- 8.5.4.3. Competitive scenario
- 8.5.4.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
- 8.6. Europe
- 8.6.1. Europe: SWOT Analysis
- 8.6.2. UK
- 8.6.2.1. Key country dynamics
- 8.6.2.2. Regulatory framework
- 8.6.2.3. Competitive scenario
- 8.6.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
- 8.6.3. Germany
- 8.6.3.1. Key country dynamics
- 8.6.3.2. Regulatory framework
- 8.6.3.3. Competitive scenario
- 8.6.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
- 8.6.4. France
- 8.6.4.1. Key country dynamics
- 8.6.4.2. Regulatory framework
- 8.6.4.3. Competitive scenario
- 8.6.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
- 8.6.5. Italy
- 8.6.5.1. Key country dynamics
- 8.6.5.2. Regulatory framework
- 8.6.5.3. Competitive scenario
- 8.6.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
- 8.6.6. Spain
- 8.6.6.1. Key country dynamics
- 8.6.6.2. Regulatory framework
- 8.6.6.3. Competitive scenario
- 8.6.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
- 8.6.7. Norway
- 8.6.7.1. Key country dynamics
- 8.6.7.2. Regulatory framework
- 8.6.7.3. Competitive scenario
- 8.6.7.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
- 8.6.8. Sweden
- 8.6.8.1. Key country dynamics
- 8.6.8.2. Regulatory framework
- 8.6.8.3. Competitive scenario
- 8.6.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
- 8.6.9. Denmark
- 8.6.9.1. Key country dynamics
- 8.6.9.2. Regulatory framework
- 8.6.9.3. Competitive scenario
- 8.6.9.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
- 8.7. Asia Pacific
- 8.7.1. Asia Pacific: SWOT Analysis
- 8.7.2. Japan
- 8.7.2.1. Key country dynamics
- 8.7.2.2. Regulatory framework
- 8.7.2.3. Competitive scenario
- 8.7.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
- 8.7.3. China
- 8.7.3.1. Key country dynamics
- 8.7.3.2. Regulatory framework
- 8.7.3.3. Competitive scenario
- 8.7.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
- 8.7.4. India
- 8.7.4.1. Key country dynamics
- 8.7.4.2. Regulatory framework
- 8.7.4.3. Competitive scenario
- 8.7.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
- 8.7.5. Australia
- 8.7.5.1. Key country dynamics
- 8.7.5.2. Regulatory framework
- 8.7.5.3. Competitive scenario
- 8.7.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
- 8.7.6. South Korea
- 8.7.6.1. Key country dynamics
- 8.7.6.2. Regulatory framework
- 8.7.6.3. Competitive scenario
- 8.7.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
- 8.7.7. Thailand
- 8.7.7.1. Key country dynamics
- 8.7.7.2. Regulatory framework
- 8.7.7.3. Competitive scenario
- 8.7.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
- 8.8. Latin America
- 8.8.1. Latin America: SWOT Analysis
- 8.8.2. Brazil
- 8.8.2.1. Key country dynamics
- 8.8.2.2. Regulatory framework
- 8.8.2.3. Competitive scenario
- 8.8.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
- 8.8.3. Argentina
- 8.8.3.1. Key country dynamics
- 8.8.3.2. Regulatory framework
- 8.8.3.3. Competitive scenario
- 8.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
- 8.9. MEA
- 8.9.1. MEA: SWOT Analysis
- 8.9.2. South Africa
- 8.9.2.1. Key country dynamics
- 8.9.2.2. Regulatory framework
- 8.9.2.3. Competitive scenario
- 8.9.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
- 8.9.3. Saudi Arabia
- 8.9.3.1. Key country dynamics
- 8.9.3.2. Regulatory framework
- 8.9.3.3. Competitive scenario
- 8.9.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
- 8.9.4. UAE
- 8.9.4.1. Key country dynamics
- 8.9.4.2. Regulatory framework
- 8.9.4.3. Competitive scenario
- 8.9.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
- 8.9.5. Kuwait
- 8.9.5.1. Key country dynamics
- 8.9.5.2. Regulatory framework
- 8.9.5.3. Competitive scenario
- 8.9.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 9. Competitive Landscape
- 9.1. Recent Developments & Impact Analysis, By Key Market Participants
- 9.2. Company/Competition Categorization
- 9.3. Vendor Landscape
- 9.3.1. List of key distributors and channel partners
- 9.3.2. Key customers
- 9.3.3. Key company market share analysis, 2024
- 9.3.4. Thermo Fisher Scientific, Inc.
- 9.3.4.1. Company overview
- 9.3.4.2. Financial performance
- 9.3.4.3. Product benchmarking
- 9.3.4.4. Strategic initiatives
- 9.3.5. PerkinElmer Inc.
- 9.3.5.1. Company overview
- 9.3.5.2. Financial performance
- 9.3.5.3. Product benchmarking
- 9.3.5.4. Strategic initiatives
- 9.3.6. BioDot
- 9.3.6.1. Company overview
- 9.3.6.2. Financial performance
- 9.3.6.3. Product benchmarking
- 9.3.6.4. Strategic initiatives
- 9.3.7. Horizon Diagnostics
- 9.3.7.1. Company overview
- 9.3.7.2. Financial performance
- 9.3.7.3. Product benchmarking
- 9.3.7.4. Strategic initiatives
- 9.3.8. Agilent Technologies, Inc..
- 9.3.8.1. Company overview
- 9.3.8.2. Financial performance
- 9.3.8.3. Product benchmarking
- 9.3.8.4. Strategic initiatives
- 9.3.9. Abnova Corporation
- 9.3.9.1. Company overview
- 9.3.9.2. Financial performance
- 9.3.9.3. Product benchmarking
- 9.3.9.4. Strategic initiatives
- 9.3.10. LGC Biosearch Technologies
- 9.3.10.1. Company overview
- 9.3.10.2. Financial performance
- 9.3.10.3. Product benchmarking
- 9.3.10.4. Strategic initiatives
- 9.3.11. Genemed Biotechnologies, Inc.
- 9.3.11.1. Company overview
- 9.3.11.2. Financial performance
- 9.3.11.3. Product benchmarking
- 9.3.11.4. Strategic initiatives
- 9.3.12. Oxford Gene Technology IP Limited
- 9.3.12.1. Company overview
- 9.3.12.2. Financial performance
- 9.3.12.3. Product benchmarking
- 9.3.12.4. Strategic initiatives
- 9.3.13. Biocare Medical, LLC.
- 9.3.13.1. Company overview
- 9.3.13.2. Financial performance
- 9.3.13.3. Product benchmarking
- 9.3.13.4. Strategic initiatives
- 9.3.14. QIAGEN (Exiqon A/S)
- 9.3.14.1. Company overview
- 9.3.14.2. Financial performance
- 9.3.14.3. Product benchmarking
- 9.3.14.4. Strategic initiatives
- 9.3.15. GSP Research Institute, Inc.
- 9.3.15.1. Company overview
- 9.3.15.2. Financial performance
- 9.3.15.3. Product benchmarking
- 9.3.15.4. Strategic initiatives